Association between epidermal growth factor receptor mutation and chemotherapeutic efficacy in advanced non-small cell lung cancer patients
10.3760/cma.j.cn431274-20181009-01779
- VernacularTitle:EGFR基因突变类型及状态与晚期非小细胞肺癌化疗疗效的相关性
- Author:
Baoguo TIAN
1
;
Yanchun SHI
;
Ting SUN
;
Yan WANG
;
Jiexian JING
Author Information
1. 山西省肿瘤医院病因室，太原 030013
- From:
Journal of Chinese Physician
2020;22(4):521-524
- CountryChina
- Language:Chinese
-
Abstract:
Objective:The aim of the study was to investigate the association between epidermal growth factor receptor (EGFR) mutation and chemotherapeutic efficacy in advanced non-small cell lung cancer (NSCLC) patients.Methods:A total number of 490 patients with advanced non-small cell lung cancer were investigated in this retrospective study. Clinical outcomes were analyzed according to EGFR mutation status and mutation type based on Kaplan-Meier method and Cox regression model.Results:EGFR mutation was detected in 202 (41.2%) NSCLC patients. There was a trend that EGFR mutant patients had a higher response rate compared with wild type NSCLC patients, with non statistical significance (72.8% versus 66.0%, P=0.11). No difference was observed in progression free survival of first-line chemotherapy between EGFR negative and positive patients (6.00 versus 6.13 months, P=0.55). Patients harboring exon 19 deletion and exon 21 L858R point mutation derived similar progression free survival (PFS) (5.97 versus 6.23 months, P=0.79). Conclusions:EGFR mutation status and mutation type are not prognostic factors to first-line platinum-based chemotherapy in advanced NSCLC.
